来氟米特治疗IgA肾病对照研究

Effect of Leflunomide in Treatment of IgA Nephropathy

【目的】观察应用来氟米特治疗IgA肾病的疗效和安全性。【方法】收集符合条件的58例IgA肾病患者随机分为2组,实验组接受来氟米特治疗,对照组接受福辛普利治疗,观察治疗前、后2、4、6、8、12、16、20、24及28周的相关临床指标变化,并进行评价。【结果】实验组治疗后24h尿蛋白定量显著减少(P<0.05),血清白蛋白显著升高(P<0.05),完全缓解率为61%,总有效率为71%。与对照组比较疗效无显著性差异(P>0.05),实验组的不良反应轻微,病人耐受性良好。【结论】来氟米特可以作为治疗IgA肾病的选择之一。

[ Objective ] To investigate the effect and safety of leflunomide in treatment of IgA nephropathy. [Methods] Fifty-eight IgA nephropathy patients were divided into two groups at random. The patients in test group received leflunomide treatment; the patients in control group received fosinopril. Clinical data were observed and evaluated in the 2nd, 4th, 6th, 8th, 12th, 16th, 20th, 24th, and 28th weeks. [Results] After receiving leflunomide therapy, the proteinuria in the test group decreased significantly （P〈 0.05）; serum albumin increased significantly （P〈 0.05） . The complete relieving rate was 61%; the total efficient rate was 71%. Contracted with fosinopril, the efficiency of leflunomide on treating IgA nephropathy was not statistically different （P 〉0.05）. The side effects were mild, and ＇all patients tolerated this therapy. [Conclusion] Leflunomide is one of the choices in treating IgA nephropathy .